Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News argenx SE ARGX

argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others.


Recent & Breaking News (NDAQ:ARGX)

argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017

GlobeNewswire November 2, 2017

argenx reports third quarter 2017 financial results and provides business update

GlobeNewswire October 26, 2017

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

GlobeNewswire September 26, 2017

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

GlobeNewswire September 25, 2017

Invitation to the extraordinary shareholders' meeting

GlobeNewswire September 22, 2017

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

GlobeNewswire September 20, 2017

argenx reports second quarter business update and half-year 2017 financial results

GlobeNewswire August 24, 2017

argenx announces publication in Nature Medicine of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116 for the treatment of dyslipidemia

GlobeNewswire August 23, 2017

argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017

GlobeNewswire August 17, 2017

argenx to Present at Wedbush PacGrow Healthcare Conference

GlobeNewswire August 8, 2017

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore)

GlobeNewswire July 7, 2017

argenx receives second preclinical milestone payment in collaboration with LEO Pharma

GlobeNewswire June 20, 2017

argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malignant Lymphoma (ICML)

GlobeNewswire June 14, 2017

argenx to Present at JMP Securities Life Sciences Conference

GlobeNewswire June 13, 2017

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  June 12, 2017

argenx announces closing of NASDAQ IPO

GlobeNewswire May 23, 2017

argenx announces full exercise of underwriters' option to purchase additional ADSs

GlobeNewswire May 19, 2017

Nasdaq Welcomes argenx (Nasdaq: ARGX) to The Nasdaq Stock Market

GlobeNewswire May 18, 2017

argenx (Nasdaq: ARGX) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO

GlobeNewswire May 18, 2017